Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Drug Discovery Spotlight: Mixed Results for Lilly, Biogen Alzheimer’s Drugs; Europe Approves Amgen’s Repatha

By Drug Discovery Trends Editor | July 24, 2015

This week’s Alzheimer’s Association International Conference (AAIC) in Washington, D.C. delivered highly anticipated data, but not all lived up to the expectation of researchers and investors. Read about this news and more.

New Data on Lilly, Biogen Alzheimer’s Drugs Show Mixed Results

Lilly’s experimental drug, solanezumab, failed to present the desired effect of ridding the brain of amyloid plaques, but the company said it saw an effect in slowing down Alzheimer’s disease in its earliest stages. Meanwhile, Biogen’s aducanumab fell short of its desired expectation: that its 6 mg dose would provide the right combination of effectiveness, with less of a brain-swelling side effect seen with other doses.

HIV discoverer: ‘To develop a cure is almost impossible‘

So says the woman who co-discovered HIV in 1983, and won a Nobel Prize for her work. French scientist Francoise Barre-Sinoussi, who will retire next month from her lab, spoke with CNN at this week’s International AIDS Society Conference, in Vancouver, about activism, the future of HIV and why there’s still no cure.

Allergan Is Using Emojis to Target Millennial Women

Forbes staff writer Sarah Hedgecock discusses Allergan’s recent campaign, #ActuallySheCan. Hedgecock says the campaign, which aims to use hashtags and emojis to engage women about birth control, “feels clumsy.” She speaks with Allergan executives Bill Meury and Herm Cukier for their takes on the new campaign.

​Drugmakers like Gilead, Mylan and Novo — not Big Pharma — are job creators

FiercePharma’s Eric Palmer reports on Big Pharma’s employment numbers versus the ‘midtier players,’ who’ve added a substantial number of jobs last year. For instance, Bayer added 5,700 employees last year, while Baxter and Mylan added 5,000 each, according to a new report from EPVantage of EvaluatePharma.

Europe Approves Amgen’s First-In-Class Cholesterol Drug

Amgen received European approval for its first-of-a-kind cholesterol drug, Repatha, which lowers levels of the artery-clogging substance more than other prescribed drugs. The decision offers a new option for patients at risk for heart disease, in a landscape where statins have been the standard treatment for over 20 years.

​Biogen Slashes 2015 Forecast as MS Drug Sales Disappoint

Sales of Biogen’s roster of multiple sclerosis drugs failed to meet analysts’ expectation, prompting the company to slash its full-year profit and sales forecast. The company’s shares fell 8.6 percent to $352 in trading before the bell on Friday.


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE